These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. ; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715 [TBL] [Abstract][Full Text] [Related]
25. Single Institution Experience of Intravitreal 0.18-mg Fluocinolone Acetonide Implant for Noninfectious Uveitis. Reddy AK; Pecen PE; Patnaik JL; Palestine AG Ophthalmol Retina; 2023 Jan; 7(1):67-71. PubMed ID: 35820567 [TBL] [Abstract][Full Text] [Related]
26. Long-term management of non-ischemic central retinal vein occlusion with fluocinolone acetonide intravitreal implant 190 μg (ILUVIEN®). Coelho J; Pessoa B; Meireles A Ther Adv Ophthalmol; 2019; 11():2515841418820755. PubMed ID: 30643869 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW; Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922 [TBL] [Abstract][Full Text] [Related]
28. BILATERAL INTRAVITREAL 0.19-MG FLUOCINOLONE ACETONIDE IMPLANT FOR PERSISTENT NONDIABETIC CYSTOID MACULAR EDEMA AFTER VITRECTOMY. Ong SS; Walter SD; Chen X; Thomas AS; Finn AP; Fekrat S Retin Cases Brief Rep; 2021 May; 15(3):261-265. PubMed ID: 30015770 [TBL] [Abstract][Full Text] [Related]
29. Treatment of intractable posterior uveitis in pediatric patients with the fluocinolone acetonide intravitreal implant (Retisert). Patel CC; Mandava N; Oliver SC; Braverman R; Quiroz-Mercado H; Olson JL Retina; 2012 Mar; 32(3):537-42. PubMed ID: 21963487 [TBL] [Abstract][Full Text] [Related]
30. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Jaffe GJ; Martin D; Callanan D; Pearson PA; Levy B; Comstock T; Ophthalmology; 2006 Jun; 113(6):1020-7. PubMed ID: 16690128 [TBL] [Abstract][Full Text] [Related]
31. Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN Carneiro A; Meireles A; Castro Sousa JP; Teixeira C Ther Adv Ophthalmol; 2020; 12():2515841420917768. PubMed ID: 32548568 [TBL] [Abstract][Full Text] [Related]
32. Efficacy of the Fluocinolone Acetonide (Yutiq) Intravitreal Implant as Monotherapy for Uveitis. Mahmud H; Ahmad TR; Gonzales JA; Stewart JM Ocul Immunol Inflamm; 2023 Oct; 31(8):1603-1607. PubMed ID: 35793136 [TBL] [Abstract][Full Text] [Related]
33. Effect of a Fluocinolone Acetonide Insert on Recurrence Rates in Noninfectious Intermediate, Posterior, or Panuveitis: Three-Year Results. Jaffe GJ; Pavesio CE; Ophthalmology; 2020 Oct; 127(10):1395-1404. PubMed ID: 32624244 [TBL] [Abstract][Full Text] [Related]
34. Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. Jaffe GJ; Lin P; Keenan RT; Ashton P; Skalak C; Stinnett SS Ophthalmology; 2016 Sep; 123(9):1940-8. PubMed ID: 27421623 [TBL] [Abstract][Full Text] [Related]
35. Cost-Effectiveness Analysis of Fluocinolone Acetonide Intravitreal (FAI) Implant for Chronic Noninfectious Uveitis Affecting the Posterior Segment of the Eye (NIU-PS) in China. Mao X; Dai Z; Yang J; Wu Y; Xie F; Lu Y; Yu J; Chang F; Lu Y Ophthalmol Ther; 2024 Jun; 13(6):1757-1772. PubMed ID: 38676875 [TBL] [Abstract][Full Text] [Related]
36. Combined fluocinolone acetonide intravitreal insertion and glaucoma drainage device placement for chronic uveitis and glaucoma. Malone PE; Herndon LW; Muir KW; Jaffe GJ Am J Ophthalmol; 2010 May; 149(5):800-6.e1. PubMed ID: 20189158 [TBL] [Abstract][Full Text] [Related]